An Open-Label, Multicentre Pilot Study of Bosentan in Pulmonary Arterial Hypertension Related to Congenital Heart Disease

Reda Ibrahim; John T Granton; Sanjay Mehta

doi:10.1155/2006/746176

Canadian Respiratory Journal (Jan 2006)

An Open-Label, Multicentre Pilot Study of Bosentan in Pulmonary Arterial Hypertension Related to Congenital Heart Disease

Reda Ibrahim,
John T Granton,
Sanjay Mehta

Affiliations

Reda Ibrahim: Montreal Heart Institute, University of Montreal, Montreal, Quebec, Canada
John T Granton: Toronto General Hospital, University of Toronto, Toronto, Canada
Sanjay Mehta: The Centre for Critical Illness Research, Lawson Health Research Institute, London Health Sciences Centre, University of Western Ontario, London, Ontario, Canada

DOI: https://doi.org/10.1155/2006/746176
Journal volume & issue: Vol. 13, no. 8
pp. 415 – 420

Abstract

Read online

BACKGROUND: Bosentan has been shown to be a safe and efficacious treatment for idiopathic pulmonary arterial hypertension (PAH) and PAH associated with connective tissue disease. However, there are limited studies examining the benefits of bosentan in PAH associated with congenital heart disease (CHD).

Published in Canadian Respiratory Journal

ISSN: 1198-2241 (Print); 1916-7245 (Online)
Publisher: Wiley
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the respiratory system
Website: https://onlinelibrary.wiley.com/journal/7503

About the journal